Changes in nasopharyngeal carriage and serotype distribution of antibiotic-resistant Streptococcus pneumoniae before and after the introduction of 7-valent pneumococcal conjugate vaccine in Hong Kong by Chiu, SS et al.
Title
Changes in nasopharyngeal carriage and serotype distribution
of antibiotic-resistant Streptococcus pneumoniae before and
after the introduction of 7-valent pneumococcal conjugate
vaccine in Hong Kong
Author(s) Ho, PL; Chiu, SS; Chan, MY; Ang, I; Chow, KH; Lau, YL
Citation Diagnostic Microbiology and Infectious Disease, 2011, v. 71 n. 4,p. 327-334
Issued Date 2011
URL http://hdl.handle.net/10722/157658
Rights
NOTICE: this is the author’s version of a work that was accepted
for publication in Diagnostic Microbiology and Infectious
Disease. Changes resulting from the publishing process, such
as peer review, editing, corrections, structural formatting, and
other quality control mechanisms may not be reflected in this
document. Changes may have been made to this work since it
was submitted for publication. A definitive version was
subsequently published in Diagnostic Microbiology and
Infectious Disease, 2011, v. 71 n. 4, p. 327-334. DOI:
10.1016/j.diagmicrobio.2011.09.006
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 1 
DMID—11-369 revised 
Changes in nasopharyngeal carriage and serotype distribution of antibiotic-
resistant Streptococcus pneumoniae before and after introduction of 7-valent 
pneumococcal conjugate vaccine, Hong Kong  
 
Pak-Leung Ho
1*
, Susan S. Chiu
2
, Maggie Y. Chan
1
, Irene Ang
1
, Kin-Hung Chow
1
, Yu-Lung 
Lau
2 
 
1
Department of Microbiology and 
2
Department of Paediatrics and Adolescent Medicine, The 
University of Hong Kong, Pokfulam Road, Hong Kong Special Administrative Region, 
CHINA  
 
Keywords: Streptococcus pneumoniae, drug resistance, serotype, prevalence 
 
 
*corresponding author: Division of Infectious Diseases, Department of Microbiology and 
Centre of Infection, The University of Hong Kong, Queen Mary hospital, Pokfulam Road, 
Pokfulam, Hong Kong SAR, CHINA. Tel.: +852-2855 4897; fax: +852-2855 1241. 
E-mail address: plho@hkucc.hku.hk (P. L. Ho). 
 
*Manuscript
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 2 
Abstract 
This study assessed the changes in serotype distribution and antibiotic resistance of 
Streptococcus pneumoniae isolates in children before and after introduction of the 7-valent 
pneumococcal conjugate vaccine (PCV7) in Hong Kong. Nasopharyngeal specimens were 
collected from 1978 and 2221 children (ages, 2 to 6 years) attending day care centers or 
kindergartens in period 1 (1999-2000) and period 2 (2009-2010), respectively. Carriage of 
PCV7 serotypes decreased from 12.8% to 8.6% (P<0.01). The relative contribution of PCV7 
serotypes 14 and 18C had decreased while that for non-PCV7 serotypes 19A, 6A, 6C, 23A 
and 15B had increased. In period 2, PCV7 penetration rate (at least one dose) for children 
aged 2, 3, 4 and 5 years were 43%, 35.7%, 26.7% and 20.4%, respectively. In multivariate 
analysis, PCV7 use was the only independent variable associated with fewer PCV7 serotypes 
carriage (OR 0.5, P=0.001). In period 2, high rates of dual penicillin/erythromycin 
nonsusceptibility were found in serotypes 6B (77.3%), 14 (100%), 19F (100%), 23F (78%), 
19A (75%), 6A (87.8%), 6C (59.3%) and 23A (78.9%). 
169 words 
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1. Introduction 
 Streptococcus pneumoniae is a major cause of childhood infections (Ho et al., 2006b; 
Ho et al., 2006a; Ho et al., 2007). In western countries, the introduction of the 7-valent 
pneumococcal conjugate vaccine (PCV-7) has led to drastic decline in the incidence of 
invasive pneumococcal disease (IPD) caused by serotypes included in the vaccine (Dagan, 
2009a; Pilishvili et al., 2010). The vaccine also protects against carriage of those serotypes in 
the vaccinated children (Hanquet et al., 2010; Huang et al., 2009). Consequently, there is 
reduced transmission of these serotypes by vaccinated children; resulting an extension of 
protection to unvaccinated population (i.e. herd immunity) (Centers for Disease Control and 
Prevention, 2005). However, these benefits have been partly offset by an increase in the 
incidence of diseases caused by serotypes not included in the vaccine; the magnitude of such 
replacement remained low relative to the reduction in PCV7 diseases (Pilishvili et al., 2010). 
In February 2010, the Food and Drug Administration in the United States approved a 13-
valent pneumococcal vaccine (PCV13) which provides coverage for the seven serotypes 
common to PCV7 and six additional serotypes (1, 3, 5, 6A, 7F and 19A) (Centers for Disease 
Control and Prevention, 2010b). In the United States, PCV13 has been recommended to 
replace PCV7 in the childhood immunization program from February 2010 onward (Centers 
for Disease Control and Prevention, 2010b). The policy change is expected to further reduce 
IPD in the United States (Centers for Disease Control and Prevention, 2010a).  
 In Hong Kong, PCV7 has been available in the market since October 2005. The 10-
valent pneumococcal conjugate vaccine (PCV10) and PCV13 were later marketed in August 
2009 and May 2010, respectively (Ho et al., 2011). In Asia, Hong Kong is one of the first 
cities to introduce PCV7 into the childhood immunization program and this was implemented 
since September 2009 (Centre for Health Protection, 2011a). The immunization schedule 
consists of a standard three-dose primary series (at 2, 4 and 6 months of age) and a booster 
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dose at 12-15 months. Before its introduction into the childhood immunization program, 
PCV7 was available as a self-financed item and its uptake in the vaccine target population 
had been low (Ho et al., 2011). In our locality, the effect of the introduction of PCV7 to the 
market and before its full implementation through the childhood immunization program upon 
IPD was recently reported by our group (Ho et al., 2011). In children <5 years, our data 
showed that the proportion of PCV7 serotypes had declined from 89.5% in 1995-2001 to 
65.7% in 2007-2009 (Ho et al., 2011). The current study was conducted to assess the changes 
in serotype distribution and antibiotic resistance of nasopharyngeal isolates prior to and 
during the early introduction of PCV7 in Hong Kong.  
 
2. Materials and method 
2.1 Study design and data collection 
Nasopharyngeal specimens were collected from children between 2 and 6 years of age 
who attend day care centers (DCC) or kindergartens (KG) in Hong Kong during September 
2009 to April 2010 (period 2). A similarly designed study was conducted during December 
1999 and June 2000 (period 1) (Chiu et al., 2001). The same recruitment process and 
sampling strategy was used in this and the previous study (Chiu et al., 2001). In brief, Hong 
Kong is divided into 18 school districts, and the sample size of each district was calculated 
according to the number of DCC and KG places in each district. Ages of children who attend 
DCC and KG range from 2 to 6 years and 3 to 6 years, respectively. Normally, all children 
attend 5 days per week for 7 to 9 hours a day in DCC and for 3 to 4 hours a day in a KG. Out 
of the total of 147,516 DCC and KG places, DCC accounted for 30% while KG accounted for 
70%. This ratio was used to calculate the number of children to be recruited from DCC and 
KG from each district to make the targeted study population of about 2000. Parental consent 
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 5 
was obtained by the research staff. The protocol is approved by the Institutional Review 
Board at the Hong Kong West Cluster/University of Hong Kong.  
As in the previous study (Chiu et al., 2001), a standardized questionnaire was used to 
obtain the following information from parents of participating children: household size, 
overcrowding (≤5.5 m/person in accordance with the guideline of the Hong Kong Housing 
Authority), number and age of siblings, participant demographics, medical history, presence 
of symptoms of upper respiratory tract infection (URTI) symptoms at the time of sampling, 
recent use of antibiotics (past 3 months), vaccination history, physician visits (past 3 months) 
and prior hospitalization (past 1 year).  
 
2.2 Specimen collection and microbiological methods 
A calcium alginate-tipped swab on a flexible aluminum wire (TRANSWAB per nasal; 
Medical Wire and Equipment Co. Ltd, Corsham, Wilts, England) was used. The specimens 
were brought back to the laboratory immediately for processing. For selective isolation of S. 
pneumoniae, swabs were inoculated onto 5% horse blood agar supplemented with gentamicin 
(2 g/ml) and incubated in 5% CO2 for 16 to 24 hours. All isolates were identified by colony 
morphology, Gram stain, optochin susceptibility, and bile solubility. Isolates with atypical 
optocin/bile solubility test results were confirmed by a slide co-agglutination test (Phadebact 
Pneumococcus Test, Remel).  
Susceptibility of the isolates to antibiotics was determined by Etest (AB Biodisk, 
Solna, Sweden) or the disc diffusion method. The D-test was used to detect inducible 
resistance to clindamycin. Quality control strains were included on each day of testing. All 
results were interpreted according to the Clinical Laboratory Standards Institute (Clincal and 
Laboratory Standard Institute, ). Pneumococcal isolates were serotyped by PCR assays and/or 
the quellung reactions. The isolates were initially tested by a sequential multiplex PCR 
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 6 
approach. Strains that could not be serotyped by the PCR assays and those that required 
further testing to the serotype level were then tested by the quellung method with sera of 
various reactivities from the Statens Seruminstitut (Copenhagen, Denmark) (Ho et al., 2004; 
Pai et al., 2006). The serotypes distribution for the isolates collected in period 1 has been 
previously reported but the method do not allow some subtypes to be distinguished (Ho et al., 
2004). Hence, all the isolates (n=163) that could not be identified the serotype level and those 
that were designated an untypeable at that time were retrieved and tested again by PCR 
methods (Pai et al., 2006). PCR assays were used to identify the newly described 6C and 6D 
serotypes (Ho et al., 2010). All serogroup 6 isolates, including those collected in period 1 
were tested by PCR assays that could distinguish the 4 subtypes (6A-6D) of serogroup 6 
isolates. All isolates were tested in a uniform manner. 
 
2.3 Statistical analysis 
 Data from the two similarly designed studies was pooled and compared. The sampling 
periods, 1999-2000 (period 1) and 2009-2010 (period 2), were intended to indicate time 
windows before and after the registration and marketing of PCV7 in Hong Kong, respectively. 
The serotype coverage for the 7-valent, 10-valent and 13-valent PCVs for carriage was 
calculated as the proportion of all isolates included in the vaccine formulations, without 
taking into account the potential serogroup cross-protection. In view of the demonstrated 
efficacy of PCV7 for serotype 6A, additional coverage due to this cross protection was also 
calculated. The Chi square or Student’s t test was used to compare participant demographics, 
pneumococcal carriage rates and serotype frequencies between the two collection periods. 
Potential risk factors for carriage of PCV7 were studied by univariate analysis. Variables that 
were significant in the univariate analysis were further analyzed by logistic regression using 
the forward-conditional method. The correlation between PCV7 penetration and reduction in 
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carriage of PCV7 serotypes by age groups was analyzed by the Correlate Bivariate analysis. 
A P value of <0.05 was considered to indicate statistical significance. All statistic analysis 
was performed by the SPSS statistic package.  
 
3. Results 
3.1 Demographics 
There were 1978 and 2211 child participants in period 1 and period 2, respectively. 
As shown in Table 1, there are some differences in the characteristics of the children 
recruited in the two periods. The average age for period 2 children was significantly younger 
than that for period 1 children. Four variables were less common among period 2 children: 
recent antibiotic use, overcrowding, URTI at time of sampling and physician visits. However, 
about twice as many children had history of prior hospitalization in period 2 than in period 1. 
The two groups of children had similar household size and number of siblings. 
As PCV7 has only been available in Hong Kong after October 2005, no children had 
been vaccinated with PCV7 in period 1. Among children recruited in period 2, the PCV7 
vaccine penetration (at least one dose) was 28.1% (622/2211). PCV7 vaccination was 
significantly more likely in younger children than in older children. The age-stratified PCV7 
penetration rate was 20.4% (149/731) among children aged 5 years, 26.7% (203/759) among 
children aged 4 years, 35.7% (196/549) among children aged 3 years and 43% (74/172) 
among children aged 2 years (P <0.001, chi square for trend). The age at first vaccination 
could be obtained from 366 children. Among these children, 20.5% (75/366) were vaccinated 
at age ≤1 year, 49.7% (182/366) at age 2 years and 29.8% (109/366) at age 3-5 years. At the 
time of sampling, 80.7% (502/622) of the vaccinated children could be considered age 
appropriately vaccinated for PCV7. In period 2, 26.1% (578/2211) children had received 
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 8 
influenza vaccination in past year. Information about influenza vaccination was not obtained 
for period 1.  
 
3.2 Serotype distribution  
 A total of 730 isolates were included in the study, comprising 383 isolates collected in 
period 1 and 347 isolates in period 2. PCV7 serotypes included 443 isolates, PCV13-
nonPCV7 serotypes included 90 isolates and non-PCV13 serotypes included 207 isolates. 
Table 2 showed the serotype distribution of the isolates according to these PCV categories for 
the two collection periods. In both collection periods, the three most prevalent serotypes were 
6B, 19F and 23F. The prevalence of seven serotypes had significantly changed during the two 
time periods. The two serotypes that had become less common in period 2 were 14 (8.9% vs. 
2.6%, P<0.01) and 18C (2.1% vs. 0.6%, P=0.049). The five serotypes that had significantly 
increased in prevalence were 19A (0% vs. 2.3%, P<0.001), 6A (3.4% vs. 11.8%, P<0.001), 
6C (1.8% vs. 7.8%, P<0.001), 23A (1.6% vs. 5.5%, P=0.003) and 15B (0.3% vs. 2.6%, 
P=0.007).   
 
3.3 Changes in pneumococcal conjugate vaccine coverage over time 
 Table 2 also showed that the serotype coverage of PCV7 had significantly decreased 
from 66.1% in period 1 to 54.8% in period 2 (P = 0.001). The reduction in the serotype 
coverage of PCV7 was greater among isolates obtained from younger children. The serotype 
coverage of PCV7 in period 1/period 2 for children of different ages was as follows: 2 year 
(94.1%/41.3%), 3 years (69.5%/56.2%), 4 years (69.1%/57.4%) and 5 years (59.8%/54%), 
respectively. Due to the absence of serotypes 1, 5 and 7F, serotype coverage of PCV7 and 
PCV10 was the same. The serotype coverage of PCV13 was similar in period 1 and period 2, 
being 72.6% and 70.6% for all ages, respectively. In period 1, the difference in serotype 
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 9 
coverage of PCV7 (66.1%) and PCV13 (72.6%) approached but did not reach statistical 
significance (P=0.05). In period 2, serotype coverage of PCV13 was 15.9% higher than that 
of PCV7 (P<0.001, 95% confidence interval for difference, 8.7 – 22.8%). However, if 
complete cross protection against 6A was assumed, the difference in serotype coverage of 
PCV13 and PCV7 became insignificant (4%, 95% CI -2.9% to 10.9%).   
 
3.4 Changes in pneumococcal carriage over time 
Overall, the nasopharyngeal carriage rate in period 2 was 15.7% (347/2221) which 
was lower than that in period 1 (19.4%, 383/1978, P < 0.01). However, the carriage rate of 
penicillin-nonsusceptibile (Pen-NS) S. pneumoniae in the two periods remained unchanged 
(11.3% vs. 11.1%, P = 0.8). Table 3 showed that the carriage rate of PCV7 isolates had 
significantly decreased from 12.8% (253/1978) in period 1 to 8.6% (190/2211) in period 2 (P 
<0.001). The decline in PCV7 carriage was most remarkable among children aged 2 years 
(from 27.1% to 7.0%) and 3 years (from 22.7% to 9.1%). The changes among children aged 4 
years and 5 years were only modest. After stratification by age, the magnitude of reduction in 
PCV7 carriage was found to correlate positively with the PCV7 penetration rate (correlate 
bivariate analysis, Pearson correlation = 0.99, P = 0.01). The carriage rate for PCV13-
nonPCV10 types showed a nearly 100% increase from 1.3% (25/1978) to 2.5% (55/2211) (P 
< 0.001). Increases in PCV13-nonPCV10 serotypes were greatest in children aged 2 years but 
the difference was not statistically significant. The prevalence of non-PCV13 carriage remain 
unchanged over the two time periods (5.3% [105/1978] vs. 4.6% [102/2211], P = 0.5).  
To further understand how availability of PCV7 might have affected pneumococcal 
carriage, the data for children enrolled in period 2 was subjected to univariate and 
multivariate analyses. Univariate analysis showed that overcrowding had positive correlation 
with PCV7 carriage (odds ratio [OR] 1.8, 95% CI 1.03-3.2; P=0.04) while a history of PCV7 
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 10 
vaccination had negative correlation (OR 0.5, 95% CI 0.3-0.8; P=0.001). The PCV7 carriage 
rate in children who were age appropriately vaccinated for PCV7 was significantly lower 
than those who were not (4.8% vs. 9.7%, respectively, P < 0.001). No statistically significant 
association between PCV7 carriage and the other child characteristics (recent antibiotic use, 
prior hospitalization, respiratory symptoms at time of sampling, having young siblings aged 
≤5 years and recent physician visit) were found. In the logistic regression, a history of PCV7 
vaccination was the only variable significantly associated with a lower chance of PCV7 
carriage (OR 0.5, 95% CI 0.3-0.7; P=0.001). On the other hand, the carriage rates for PCV13-
nonPCV10 (2.2% vs. 2.6%, P = 0.6, respectively) and non-PCV13 (5.2% vs. 4.4%, P = 0.5, 
respectively) isolates were similar among children who were and were not age appropriately 
vaccinated for PCV7.  
In period 1, a history of recent use of antibiotics was significantly associated with 
carriage of penicillin-nonsusceptible S. pneumoniae (Odds ratio [OR] 1.9, 95% confidence 
interval [CI], 1.2-2.9, P=0.003) but not with erythromycin-nonsuceptible S. pneumoniae 
(P=0.2). In period 2, on the contrary, recent use of antimicrobial agents was significantly 
associated erythromycin-nonsuceptible S. pneumoniae (OR 4.7, 95% CI, 1.7-14.0) but not 
with penicillin-nonsusceptible S. pneumoniae (P=0.2). 
 
3.5 Changes in antimicrobial susceptibility over time 
 Table 4 summarized the serotype-specific antimicrobial susceptibility rates of the 
isolates for the two collection periods. Overall, it showed that the rates of penicillin 
nonsusceptibility (meningitis breakpoint, 58.2% vs. 70.6%, for period 1 vs. period 2, 
respectively, P<0.001), erythromycin nonsusceptibility (77.0% vs. 86.7%, for period 1 vs. 
period 2, respectively, P<0.001), and dual penicillin/erythromycin nonsusceptibility (52.5% 
to 70.3%, for period 1 vs. period 2, respectively, P<0.001) had significantly increased over 
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time. There was no significant change in nonsusceptibility rate for levofloxacin (0% vs. 0.3%) 
over time. The capsular serotype of the only isolate with resistance to levofloxacin (MIC 16 
g/ml) was 19F. 
Stratification by serotype showed that the penicillin and dual penicillin/erythromycin 
nonsusceptibility rates for serotypes 19F, 14, 6A and 23A had significantly increased over the 
two time periods. The changes for serotype 6A were most dramatic. The erythromycin 
nonsusceptibility rates for these serotypes were similar in the two time periods. In period 1, 
five serotypes (6B, 19F, 23F, 14 and 6C) were often nonsusceptible to both penicillin and 
erythromycin with rates of 42.9% to 86.5%. In period 2, these serotypes continued to exhibit 
high rates of dual penicillin/erythromycin nonsusceptibility (59.3% to 100%). Besides these, 
an additional three serotypes (19A, 6A and 23A) were found to exhibit high rates of dual 
penicillin/erythromycin nonsusceptibility (75% to 87.8%). No serotype 19A was found in 
period 1. Six (75%) of the eight serotype 19A isolates found in period 2 were nonsusceptible 
to both penicillin and erythromycin.  
 PCV7 covered significantly fewer dual penicillin/erythromycin-nonsusceptible 
isolates collected in period 2 than in period 1 (66% vs. 93.5%, respectively, P<0.001). 
Although PCV13 covered more isolates, the serotype coverage for dual 
penicillin/erythromycin-nonsusceptible isolates in period 2 was still lower than that for period 
1 (83.1% vs. 94.0%, respectively, P<0.001). 
Figure 1 showed a scatter plot of the serotype-specific prevalence with the penicillin-
nonsusceptibility rates. Curve fitting and linear regression revealed that the two variables had 
significant associations for both time periods. The correlation coefficient was higher in period 
1 (R-square = 0.74, P<0.001) than in period 2 (R-square = 0.43, P<0.001). Weaker but still 
statistically significant correlations were obtained for erythromycin nonsusceptibility. The 
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finding showed that antimicrobial resistance could be an important determinant of the 
serotype prevalence. 
 
4. Discussion 
This study assessed the changes in incidence of pneumococcal carriage, antimicrobial 
resistance rates and serotype distribution of nasopharyngeal isolates prior to and during early 
introduction of PCV7 in Hong Kong. The carriage of PCV7 serotypes was found to have 
declined significantly, especially among younger children in whom the vaccine penetration is 
higher. This was partially off-set by a slight increase in the non-PCV7 serotypes. The net 
effect was that children were less likely to carry pneumococci in the latter period. This 
occurred at a time when the vaccine update was still low (20.4% to 43%) among children 
aged 2 to 5 years. Consequently, fewer isolates recovered in period 2 were included in the 
PCV7 formulation than in period 1. These observations were in agreement with experiences 
in places where PCV7 was made readily available earlier (Dagan, 2009b; Huang et al., 2009; 
Sa-Leao et al., 2009). However, not all the seven PCV7 serotypes had decreased and overall 
carriage of types included in PCV7 was still high. The types that had declined significantly 
were serotype 14 and 18C. This may be explained by variations in the vaccine efficacy for 
the different serotypes (Whitney et al., 2006). In the Kaiser PCV7 efficacy study, the 
geometric mean concentration of pneumococcal antibodies was found to be highest for 
serotype 14, followed by serotype 18C and 6B (Black et al., 2000). The antibody level 
concentrations for the remaining serotypes were similar (Black et al., 2000). Since the 
vaccine uptake was low, it might take longer for the other serotypes to decrease. While 
conjugate vaccines confer protection against carriage of types included in the vaccines and 
occasionally other types in the same serogroups, they provide no protection against 
serogroups that are not included in the vaccine. Therefore, conjugate vaccine use might be 
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expected to contribute to the observed increase in non-PCV7 types (19A, 6A, 6C, 23A and 
15B). Nonetheless, we were unable to demonstrate any association between PCV7 use and 
carriage of these serotypes.  
In our locality, similar temporal changes have also been demonstrated among isolates 
causing invasive disease in children (Ho et al., 2011). Among children aged <5 years, the 
frequencies of serotype 14 and 18C had decreased from 36% to 15.7% and from 4.7% to 0%, 
respectively, before (1995-2001) and shortly after (2005-2009) introduction of PCV7 to the 
Hong Kong market (Ho et al., 2011). Over the same time periods, invasive disease caused by 
serotype 19A had increased from 0% to 12.9% and serotype 6A increased from 2.3% to 7.1% 
(Ho et al., 2011). Despite marked increases in prevalence of serotypes 6C, 15B and 23A 
among isolates causing nasopharyngeal colonization, such serotypes were rarely found 
among our invasive isolates. Although almost all children become colonized with 
pneumococci during the first few years of life, only a small faction of the colonization 
proceed to invasive disease. In pneumococci, the capsular polysaccharide is assumed to be 
the most important factor that determine the capacity of specific strains to cause invasive 
diseases (Melin et al., 2010). According to one report, the invasive capacity of different 
pneumococcal serotypes was found to vary by as many as 50 folds (highest for 3, 7F, 18C, 
19A,  22F and 33F; while 6C, 15B and 23A were among the serotypes with the lowest 
invasive capacity) (Yildirim et al., 2010). This could explain why increasing carriage of 
serotypes 6C, 15B and 23A was not associated with corresponding changes in invasive 
disease.  
 Besides pneumococcal conjugate vaccine use, excessive antibiotic use is another well-
established factor exerting pressure on pneumococcal ecology; with incorrect usage leading 
to an increase in multidrug-resistant strains population. In Hong Kong, antimicrobials (such 
as oral amoxicillin-clavulanate, cephalosporins and macrolides) are frequently prescribed to 
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children with febrile illnesses (Lam et al., 2009). Although the frequencies of recent 
antibiotic uses in period 2 were slightly lower than those in period 1 (Chiu et al., 2001), the 
30.6% among participating children and 27% among their household members still 
constituted substantial consumption. Such high antibiotic uses partly reflect widespread 
misconceptions about antibiotics among the laypersons in our community (Centre for Health 
Protection, 2011b). In a territory-wide telephone survey conducted in November 2010, 66.9% 
of 1569 respondents believed that antibiotics are effective in treating viral infections (Centre 
for Health Protection, 2011b). Thus, the observed association between penicillin 
nonsusceptibility and serotype prevalence is not surprising. Heavy antibiotic use could exert 
pressure through selection of resistance in previously minor serotypes and subsequent clonal 
expansion (Huang et al., 2009). Alternatively, pre-existing resistant clones could undergo 
capsular switching and disseminate as non-vaccine serotypes (Ansaldi et al., 2011; Moore et 
al., 2008). Our finding that a history of recent antibiotic use was associated with different 
types of antibiotic-resistant S. pneumoniae in the two time periods corroborated previous 
studies that the relationship between exposure to antibiotics and the spread of resistant 
pneumococci is complex (Huang et al., 2009). Since details of the recent antibiotic use were 
not collected, we were unable to conduct analysis according to antibiotic class, duration of 
use and dosage. Unless antibiotic usage are curtailed, the overall antimicrobial resistance 
among pneumococci would remain high (Dagan, 2009b; Sa-Leao et al., 2009). 
 The observed increases in prevalence of non-PCV7 serotypes such as 19A, 6C, 23A 
and 15B were broadly in line with secular trends in the developed countries following the 
introduction of PCV7 (Hanage et al., 2005; Huang et al., 2009). In Asian countries, 
emergence of the non-PCV7 serotype 19A has been associated with expansion of multidrug-
resistant ST320 isolates and could be unrelated to PCV7 use (Choi et al., 2008; Ho et al., 
2011; Shin et al., 2011). Nonetheless, marked variations in the prevalence of serotype 19A 
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were observed. According to a multi-national surveillance (Shin et al., 2011), the prevalence 
of serotype 19A among clinical isolates in 2008-2009 was high in India (13.0%), Japan 
(11.1%), South Korea (9.9%), Malaysia (9.1%), and Saudi Arabia (9.0%), but low in Hong 
Kong (3.1%), Taiwan (4.8%), Thailand (5.2%), the Philippines (1.7%), and Vietnam (0.4%). 
It is recognized that antibody induced by the 6B component in PCV7 may provide cross 
protection against the vaccine-related serotype 6A (Whitney et al., 2006). However, we found 
that the prevalence of serotype 6A among nasopharyngeal isolates has increased and were 
associated with emergence of dual penicillin/erythromycin nonsusceptibility in this serotype. 
We have excluded potential confounding with other highly similarly subtypes by using 
methods that could differentiate 6A from the other closely related 6C and 6D types to analyze 
all the isolates. Since the strains were antibiotic-resistant, the finding may be partly 
explainable by selection pressure exerted by heavy antibiotic usage. In southern Israel, 
increases in multidrug-resistant serotype 6A among Bedouin children have been associated 
with expansion of ST457 prior to the introduction of PCV7 (Porat et al., 2010). Future studies 
to investigate the bacterial population structure underlying the observed increases in the five 
serotypes (6A, 6C, 19A, 23A and 15B) are warranted.  
 In conclusion, this study showed that the proportion of several serotypes among 
pneumococci carried by children in Hong Kong have changed following the availability of 
PCV7 and to a lesser extent, PCV10 as self-financed items. Although PCV10 was also 
available in the market, no children enrolled in period 2 reported prior PCV10 immunization 
indicating its usage at that time was very low. Despite some favorable reduction in the 
vaccine-related serotypes, there was little change in the carriage of antimicrobial-resistant 
pneumococci and the rates of penicillin and erythromycin resistance among the carried 
isolates have even increased. The change in vaccine coverage over time and the observed 
increased in serotype 6A and 19A in both invasive and nasopharyngeal isolates indicate that 
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PCV13 could provide substantial benefits over PCV7 (Ho et al., 2011). Hence, Hong Kong 
has announced to switch to PCV13 in the childhood immunization program in the last quarter 
of 2011. Such change in vaccine policy is expected to impact upon the future evolution of 
pneumococcal serotypes in this locality. Future studies should monitor how the emerging 
serotypes will evolve and attention should be paid to non-PCV13 serotypes with higher 
invasive capacity. Our finding also calls for greater attention to judicial use of antibiotics 
(Lam et al., 2009). 
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Table 1. Characteristics of children according to time periods, Hong Kong 
 % (No/total)  
 Period 1 (n=1978) Period 2 (n=2211) P 
Age, mean  SD (yr) 4.3  0.8 3.9  0.9 <0.001 
Household size, mean  SD 4.5  1.3 4.4  1.2 0.5 
Recent antibiotic use by    
subject 50.1 (883/1747) 30.6 (677/2211) <0.001 
household members 34.7 (616/1777) 27.0 (596/2211) <0.001 
Overcrowding 14.0 (277/1972) 4.8 (105/2183) <0.001 
Prior hospitalization 3.2 (63/1978) 7.5 (165/2211) <0.001 
Respiratory symptoms at time of 
sampling 
25.6 (507/1978) 9.7 (214/2211) <0.001 
Has young siblings (<=5y) 27.6 (546/1978) 27.8 (614/2211) 0.9 
Recent physician visit    
At least once 77.6 (1535/1978) 62.7 (1386/2211) <0.01 
Multiple (≥3 times) 23.7 (468/1931) 13.1 (289/2211) <0.01 
The time periods were 1999-2000 (period 1) and 2009-2010 (period 2). The data for period 1 
was extracted from a previous work (Chiu et al., 2001) and those for period 2 were collected 
in the present study. Unless specified, the figures were number (%) of children. The number 
of participating institutes for period 1 and period 2 were 79 and 191, respectively. 
 
Table(s)
  
Table 2. Comparison of the serotype distribution of nasopharyngeal isolates of 
Streptococcus pneumoniae collected in two time periods, Hong Kong  
Serotype
a 
No. (%) 
 
Period 1
 
Period 2 P 
Total  383 (100) 347 (100) - 
PCV7     
4 0 (0) 0 (0) - 
6B 88 (23.0) 75 (21.6) 0.7 
19F 69 (18.0) 62 (17.9) 0.9 
23F 52 (13.6) 41 (11.8) 0.5 
14 34 (8.9) 9 (2.6) <0.01 
18C 9 (2.3) 2 (0.6) 0.049 
9V 1 (0.3) 1 (0.3) 0.9 
PCV13-nonPCV7     
3 12 (3.1) 6 (1.7) 0.2 
19A 0 (0) 8 (2.3) <0.001 
6A 13 (3.4) 41 (11.8) <0.001 
Non-PCV13    
6C 7 (1.8) 27 (7.8) <0.001 
23A 6 (1.6) 19 (5.5) 0.003 
15B 1 (0.3) 9 (2.6) 0.007 
Others
b 
91 (23.78) 47 ((13.5) - 
Vaccine coverage    
PCV7 253 (66.1) 190 (54.8) 0.001 
PCV10 253 (66.1) 190 (54.8) 0.001 
PCV13 278 (72.6) 245 (70.6) 0.6 
a 
No PCV10-nonPCV7 serotypes (1, 5 and 7F) were found in both periods. If serotype cross 
protection for 6B and 6A was assumed, the vaccine coverage for PCV7 and PCV10 in period 
1/period 2 was both 69.5%/66.6%, respectively. 
b 
For period 1, these included 7C (n=2),  8 (n=1),  13 (n=3),  11A (n=12), 15C (n=7), 15F 
(n=6), 19B (n=3), 22F (n=1), 28A/F (n=1), 29 (n=1),  33B/C/D (n=2), 34 (n=13), 35AC/42 
(n=5), 35B (n=4), 35F (n=2) and nontypeable (n=28). For period 2, these included 8 (n=1),  
10A (n=2),  11B/F (n=1),  11D (n=2),  15C (n=23),  15F (n=6),  22F (n=1),  23B (n=1),  29 
(n=1),  33B/C/D (n=1), 34 (n=11)  35AC/42 (n=2),  35B (n=2),  35F (n=1), 37 (n=1)  and  7C 
(n=1).  
  
Table 3. Proportions of children carrying pneumococci within each sampling period, 
according to age 
 % children with carriage   
 Period 1 Period 2 Difference (95% CI) P value 
PCV7 types     
2y 27.1 7.0  -20.1 (-9.3, -32.9) <0.001 
3y 22.7  9.1  -13.6 (-8.4, -19.2) <0.001 
4y 13.9  9.7  -4.2 (-0.5, -8.0) 0.02 
5y 9.1  7.4  - 0.19 
All ages 12.8 8.6 -4.2 (-2.3, -6.1) <0.01 
PCV13-nonPCV10     
2y 1.7  7.0  - 0.19 
3y 2.4  1.6  - 0.43 
4y 1.2  2.5  - 0.12 
5y 1.0  2.1  - 0.05 
All ages 1.3  2.5  1.2 (0.4, 2.1) <0.01 
Non-PCV13     
2y 0.0  2.9  - 0.33 
3y 7.6  5.5  - 0.23 
4y 5.0  4.7  - 0.85 
5y 5.1  4.2  - 0.36 
All ages 5.3  4.6  - 0.5 
y, year
  
Table 4. Serotype distribution of nasopharyngeal isolates and their antimicrobial susceptibility according to serotype and time periods, 
Hong Kong.  
 % Pen-NS
a, b 
 % Ery-NS  % Pen/Ery-NS 
Serotype
 
Period 1 Period 2 P  Period 1 Period 2 P  Period 1 Period 2 P 
All  58.2 70.6 <0.001  77.0 86.7 <0.001  52.5 70.3 <0.001 
PCV7             
4 - - -  - - -  - - - 
6B 84.1 77.3 0.3  95.5 90.7 0.4  81.8 77.3 0.5 
19F 75.4 100 <0.001  95.7 100 0.2  75.4 100 <0.001 
23F 88.5 78.0 0.2  92.3 82.9 0.2  86.5 78.0 0.3 
14 55.9 100 0.01  97.1 100 1.0  55.9 100 0.01 
18C 0 0 -  11.1 50 0.3  0 0 - 
9V 0 0 -  100 100 -  0 0 - 
PCV13-nonPCV7             
3 8.3 0 1.0  25.0 0 0.5  0 0 - 
19A - 75.0 -  - 87.5 -  - 75.0 - 
6A 7.7 87.8 <0.001  76.9 95.1 0.08  7.7 87.8 <0.001 
Non-PCV13            
6C 42.9 59.3 0.7  85.7 96.3 0.4  42.9 59.3 0.7 
23A 0 78.9 0.001  100 100 -  0 78.9 0.001 
15B 0 22.2 1.0  0 55.6 1.0  0 22.2 1.0 
others 29.7 19.1 -  40.7 63.8 -  9.9 17.0 - 
a 
The percentages referred to the proportion of penicillin-nonsusceptible (Pen-NS, MIC >0.06 g/ml), erythromycin-nonsusceptible (Ery-NS) or 
dual penicillin/erythromycin-nonsusceptible (Pen/Ery-NS) isolates within each serotype group.  
b 
The penicillin MIC50 and MIC90 for all the isolates were 0.5 g/ml and 2 g/ml, respectively. Forty-nine isolates had penicillin MIC 4 g/ml. 
They belonged to 19F (n=35), 23F (n=9), 6B (n=2), 14 (n=1), 15C (n=1) and 19A (n=1). Two isolates had penicillin MIC 8 g/ml (both 19F).  
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Figure 1. Relationship between serotype-specific prevalence and penicillin-nonsusceptibility 
rates for (A) period 1 and (B) period 2. The line showed regression result according to the 
linear model.  
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